REVOLUTiONiZiNG MALARiA VACCiNATiON Photo credit:: PATH Malaria Vaccine inniciative

Company Founders Business development advisors

Support 100 thousand US$ 1.2 million US$ 320 thousand US$ Phase I funding 100 thousand US$ (November 2010) Phase II funding 1.2 million US$ (November 2013) Supplement to 320 thousand US$ (December 2014) Pre-clinical safety studies 280 thousand US$ (February 2016)

Problem MALARIA 2.5 billion people at risk of contracting malaria 700 thousand deaths every year 12 billion US$ in lost GDP of endemic countries NO EFFECTIVE VACCINE AVAILABLE Most advanced candidate only affords ~36% protection against a single parasite species Photo credit: Antonio M. Mendes

4.5 billion US$ global market Market potential 4.5 billion US$ global market Humanitarian market: (estimated value: 3 billion US$) Private market: (estimated value: 700 million US$) Tourist & military market: (estimated value: 800 million US$) Photo credit: NYtimes

Whole organism vaccines Vaccine Approaches Whole organism vaccines Shown to confer >90% sterile protection against a new infection in Phase I/IIa trials Serious safety concerns Extremely high dosages Do not target the most prevalent parasite, P. vivax Mandatory high biosafety BSL3 production facilities

WHOLE-ORGANISM PLATFORM FOR VACCINATION AGAINST Uniqueness Plasmodium berghei A SAFE & VERSATILE WHOLE-ORGANISM PLATFORM FOR VACCINATION AGAINST MULTIPLE HUMAN PARASITES Photo credit: worldnaturephoto.com

Pre-clinical data

Stakeholders

New Vaccine Candidates Capable of blocking parasite development at various stages of their life cycle

Production & delivery Establishment of cell culture-based production of sporozoites Development of a vaccine cryopreservation system

Cryopreservation system

Cell-culture-based production of sporozoites 400 300 200 100 3 5 10 12 15 18 21 25 Time (days) Luminescence (% of d0) d10 d3 d12 d5 d21

Strategy Vaccine Clinical Development (Market entry: 2025) Production & delivery technology (Market entry: 2018)

LET’S PUT AN END TO MALARiA Photo credit: Antonio M. Mendes